Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22829185 | 0.87 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL22829187 | 0.87 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL22839982 | 0.85 | ADRB2 (0.47) | ADRB2ADRB1CHRM3 | |
| SCHEMBL22840003 | 0.85 | ADRB2 (0.50) | ADRB2ADRB1CHRM3 | |
| SCHEMBL22829209 | 0.81 | ADRB2 (0.60) | ADRB2CHRM3 | |
| SCHEMBL22829193 | 0.81 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL22829205 | 0.81 | ADRB2 (0.60) | ADRB2CHRM3 | |
| SCHEMBL22829191 | 0.81 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL22829237 | 0.79 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CHRM3 | |
| SCHEMBL19770186 | 0.79 | ADRB2 (0.78) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |